caa a22 4500 555244067 20190211030308.0 cr unu---uuuuu 190205e20181010xx s 000 0 eng 1664-2295 10.3389/fneur.2018.00821 doi (BORIS)oai:boris.unibe.ch:124713 610 ddc 30364133 pmid Role of Family Planning in Women With Multiple Sclerosis in Switzerland: Results of the Women With Multiple Sclerosis Patient Survey [Elektronische Daten] [Christian Philipp Kamm, S. Muehl, D. Mircsof, S. Muller, A. Czaplinski, L. Achtnichts, P. Stellmes, G. Di Virgilio] publishedVersion openAccess eu-repo Background: Women of child bearing age with multiple sclerosis (MS) must carefully consider treatments when planning a family, since disease modifying drugs (DMDs) are contraindicated during pregnancy. Objectives: This questionnaire-based study aimed to improve understanding of the effect of family planning on treatment decisions in female, Swiss MS patients. Methods: Female patients with MS (aged 18-55 years) participated in the 26-question survey between September 2014 and August 2015. Information captured included patient background, family planning status, treatment course, and previous pregnancies. Results: In total, 271 questionnaires distributed from 15 MS centres were returned for analysis. Of these, 250 (92.3) participants received DMD therapy and 106 (39.1) wanted children or were pregnant. Significantly more patients with a short-term plan to conceive within 2 years were treated with injectables (19/54) compared with those without a plan to conceive (19/108; p = 0.013). A proportionally greater number of women not planning to conceive took oral (34/108) or infusion therapies (41/108) compared with those with a short- (13/54 and 16/54, respectively) or medium-term (after 2 years or more; infusion therapy only, 14/44) plan to conceive. Conclusion: The study highlights that pregnancy remains an important yet unresolved concern in the treatment of MS patients. Nearly all women received DMD treatment, and type of DMD treatment was influenced by family planning, with significantly more women with a short-term plan to conceive using injectables. Kamm Christian Philipp joint author Muehl S. joint author Mircsof D. joint author Muller S. joint author Czaplinski A. joint author Achtnichts L. joint author Stellmes P. joint author Di Virgilio G. joint author Frontiers in neurology 9(821), p. 821 1664-2295 https://boris.unibe.ch/124713/1/fneur-09-00821.pdf text/html WWW-Backlink auf das Repository 1 info:eu-repo/semantics/article boris PeerReviewed boris peerstatus BORIS 856 40 https://boris.unibe.ch/124713/1/fneur-09-00821.pdf text/html WWW-Backlink auf das Repository BORIS 700 1- Kamm Christian Philipp joint author BORIS 700 1- Muehl S. joint author BORIS 700 1- Mircsof D. joint author BORIS 700 1- Muller S. joint author BORIS 700 1- Czaplinski A. joint author BORIS 700 1- Achtnichts L. joint author BORIS 700 1- Stellmes P. joint author BORIS 700 1- Di Virgilio G. joint author BORIS 773 0- Frontiers in neurology 9(821), p. 821 1664-2295 BK010053 XK010053 XK010000 BORIS BORIS BORIS info:eu-repo/semantics/article openAccess